Drug Profile
Odiparcil - Inventiva Pharma
Alternative Names: 424323; IVA336; SB 424323Latest Information Update: 16 Feb 2022
Price :
$50
*
At a glance
- Originator Fournier Pharma
- Developer Fournier Pharma; GlaxoSmithKline; Inventiva Pharma; Solvay
- Class Antiarrhythmics; Antithrombotics; Benzopyrans; Glycosides; Ketones; Organic sulfur compounds; Small molecules; Vascular disorder therapies
- Mechanism of Action Glycosaminoglycan modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Mucopolysaccharidosis I; Mucopolysaccharidosis II; Mucopolysaccharidosis VI
- Discontinued Atrial fibrillation; Deep vein thrombosis; Stroke; Thrombosis
Most Recent Events
- 16 Feb 2022 Inventiva intends to provide development update on Odiparcil, in 2022
- 31 Dec 2021 Suspended - Phase-II for Mucopolysaccharidosis VI in Germany, Portugal, France, United Kingdom (PO), as The company focuses on the development of lanifibranor, prior to December 2021
- 31 Dec 2021 Suspended - Preclinical for Mucopolysaccharidosis I in France (PO), as The company focuses on the development of lanifibranor, prior to December 2021